Just trying to clarify this in my own mind. Biogen started a PI trial that had a 25% drop out rate leaving them with 143 patients that continued on to a longer term study. They then recruited 1350 patients in each of 2 PIII trials that a year and a half later through a futility analysis was recommended that they stop (did they actually stop dosing?). They presented data at CTAD last year that showed they were able to slow the progression of Alzheimer's by 33%, they cancelled there program, we haven't heard whether they had both of those 1350 patient studies continue uninterrupted, they announce restarting the program and now expect the FDA to approve aducanumab as a drug.

I look forward to hearing what effect apabetalone treated patients had during BETonMACE!

Am I correct in thinking that a 1% increase in cognitive function by the dosed group in BoM would be 6X's better than the dosed group in the Biogen trial?

tada